Drugs / Pancreatic Polypeptide
last change Apr 2026 re-read 2 minutes ago

Pancreatic Polypeptide

Peptide

Developed for
type 1 diabetes mellitus
Investigated by
Universitaire Ziekenhuizen KU Leuven

Trials 1 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03854708 Aug 2010 → Mar 2011 Universitaire Ziekenhuizen KU Leuven Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00791076 Comparator Oct 2007 → Jun 2010 type 1 diabetes mellitus Johns Hopkins University Terminated No outcome recorded
Phase not applicable1 trial
NCT07506369 Comparator Apr → Oct 2026 expected obesity disorder University Hospital, Gentofte, Copenhagen Recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as pancreatic polypeptide ClinicalTrials.gov intervention name — accepted as the source's own label NCT03854708
2

NCT00791076

NCT07506369

Known as Human pancreatic polypeptide ChEMBL registry synonym — accepted as the source's own label CHEMBL4540843
Known as Pancreatic hormone iii ChEMBL registry synonym — accepted as the source's own label CHEMBL4540843
Known as Pancreatic polypeptide (human) ChEMBL registry synonym — accepted as the source's own label CHEMBL4540843
Modality Peptide “pancreatic polypeptide (PP), a hormone that is naturally produced by the pancreas” NCT00791076
Route Intravenous “was intravenously infused” NCT03854708